ChrysCapital Acquires Novartis India in Strategic Acquisition

ChrysCapital has acquired Novartis India for an undisclosed amount, marking a significant transaction in the Indian pharmaceutical sector.

This acquisition sees ChrysCapital taking ownership of the established Indian operations of the global medicines company.

Novartis India has been a prominent player in the Indian healthcare landscape since 1947, focusing on reimagining medicine through innovative science and digital technologies.

The company is recognized for creating transformative treatments in areas of significant medical need and consistently ranks among the world’s top companies investing in research and development.

Its products reach nearly 1 billion people globally, with an ongoing commitment to expanding access to its latest treatments.

Novartis India is also noted for its workplace culture, having been recognized as a Great Place to Work 2025® and among Asia’s Best Workplaces 2025™, reflecting its strong organizational foundation.

The strategic rationale behind ChrysCapital's acquisition of Novartis India appears centered on leveraging the latter's deep-rooted market presence, extensive R&D capabilities, and strong brand reputation within the Indian pharmaceutical industry.

This move is expected to provide ChrysCapital with a robust platform in a critical and growing healthcare market.

Synergies are anticipated through continued investment in Novartis India's innovative approach to medicine and its established distribution networks, potentially enhancing market penetration and access to essential treatments across the region.

The combined entity is poised to continue its mission of delivering advanced medical solutions and expanding patient access in India.

This acquisition is expected to support the ongoing development of transformative treatments and reinforce the company's commitment to healthcare innovation and accessibility in the Indian market.